Read more
Aptamers Engineered Nanocarriers for Cancer Therapy details the selection technologies, biological characteristics, and clinical uses of aptamer-based nano agents for cancer therapeutics. The book helps facilitate speedy solutions for some of the problems pertaining to the manufacture of nano-aptamers - such as toxicity, thermal stability, cost efficiency, tumor penetration and blood stability. Key chapters cover cell-SELEX technology for aptamer selection, mechanisms of multi-drug resistance of cancer, the relevance of aptamers as anticancer therapies, as well as the broad range of aptamer-functionalized nanostructures available.
This book provides exciting insights into this relatively new approach to cancer therapeutics, and will be of interest to materials scientists, biomedical engineers, molecular biologists, biochemists and clinical scientists, with a focus on cancer therapy.
List of contents
1. Cell-SELEX technology for aptamer selection
2. Biological characteristics of aptamers
3. Mechanisms of multi-drug resistance of cancer
4. Relevance of aptamers as targeting ligands for anticancer therapies
5. Aptamers as smart ligands for nano-carriers cancer targeting
6. Aptamer-functionalized liposomes for targeted cancer therapy
7. Aptamer-functionalized micelles for targeted cancer therapy
8. Aptamer-functionalized nanoparticles for targeted cancer therapy
9. Aptamer-functionalized PLGA nanoparticles for targeted cancer therapy
10. Aptamer-functionalized silica nanoparticles for targeted cancer therapy
11. Aptamer-functionalized gold nanoparticles for targeted cancer therapy
12. Aptamer-functionalized dendrimers for targeted cancer therapy
13. Aptamer-functionalized carbon nanotubes for targeted cancer therapy
14. Aptamer-functionalized quantum dots for targeted cancer therapy
15. Cancer immunotherapy via nucleic acid aptamers
16. Aptamer-based imaging and diagnostics for cancer cells
17. Microdevice-based aptamer sensors
18. Aptamer-based microfluidics for circulating tumor cells
19. Aptamer-based theranostic approaches for treatment of cancer
20. Challenges of aptamers as targeting ligands for anticancer therapies
21. Clinical use and future perspective of aptamers
About the author
Dr. Prashant Kesharwani is assistant professor of Pharmaceutics at Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya, Sagar, Madhya Pradesh, India. He has more than 12 years of teaching, research, and industrial experience at international levels from various countries, including the United States, Malaysia, and India. An overarching goal of his current research is the development of nanoengineered drug delivery systems for various diseases. He has more than 350 international publications in well-reputed journals and more than 25 international books (Elsevier). He is a recipient of many research grants from various funding bodies. He is also the recipient of several internationally acclaimed awards, such as “USERN Laureate award”, most prestigious “SERB-Ramanujan Fellowship Award”. He actively participates in outreach and scientific dissemination for the service of the wider community. His Number of citations is = 26779; h-index = 85; i-10 index = 370 (According to google scholar on March 2025). He has more than 30 international publications published in very high impact factor journals (Progress in Polymer Sciences IF 32.063, Molecular Sciences IF 41.444, Progress in Material Sciences IF 48.580, Advanced Materials IF 29.4, Drug Resistance Update IF 22.841 and Material Todays IF 32.072). He has presented many invited talks and oral presentations at prestigious scientific peer-conferences, received international acclaims and awards for research contribution, supervised students/junior researchers and actively participated in outreach and scientific dissemination for the service of the wider community.
